CHF113.84 Novartis AG (NOVN.SW, SIX) pre-market 13 Jan 2026: most active, earnings watch
We see NOVN.SW stock trading at CHF113.84 in the SIX pre-market session on 13 Jan 2026, down 0.18% from the previous close. Volume sits at 2,045,536 shares against a 3-month average near 2,909,423, making Novartis one of today’s most active names on the Switzerland market. Investors are watching upcoming earnings and valuation signals as the stock trades above its 50-day average CHF106.46 and 200-day average CHF99.17.
Price snapshot and trading flow for NOVN.SW stock
Novartis AG (NOVN.SW) opened CHF112.60 and is trading at CHF113.84 in pre-market on the SIX exchange in Switzerland. The intraday range is CHF112.48-CHF114.10 and the year high is CHF114.64. Average volume is 2,909,423; today’s 2,045,536 shows below-average early flow but still marks the stock as most active.
The stock trades at PE 19.53 with EPS CHF5.83. On momentum, RSI 74.23 and Stochastic %K 92.86 signal short-term overbought conditions that can compress intraday moves despite strong multi-month gains of 8.46% over three months.
NOVN.SW stock earnings and news catalysts
Earnings and corporate catalysts drive the near-term agenda: Novartis reports next on 4 Feb 2026. That date is the chief immediate catalyst for traders building pre-earnings positions.
Recent headlines show market reference pages updating quotes and company profiles; see Bloomberg and MarketWatch for live quote and company coverage source and source. Analysts will watch margin trends in Innovative Medicines and Sandoz performance.
Fundamentals and valuation: NOVN.SW stock analysis
Fundamentals show steady cash generation: operating cash flow per share CHF10.71 and free cash flow per share CHF9.30. Dividend per share is CHF4.39, a yield near 3.07%, with payout ratio 0.54. Novartis has healthy interest coverage at 15.66 and net debt to EBITDA around 0.98.
Valuation multiples: price-to-sales 4.86, price-to-book 6.34, EV/EBITDA 12.97. Using a fair PE of 20 on EPS CHF5.83 suggests a near-term fair value of CHF116.60, close to the current price and supporting a neutral-to-positive view for long-term holders.
Technicals and most-active trading signals for NOVN.SW stock
Technical indicators show a strong near-term trend: MACD histogram 0.53, ADX 22.67, and an ATR of CHF1.69. Bollinger band upper is CHF113.98. The high RSI and CCI imply overbought short-term status and potential consolidation.
Given the stock’s 50-day average CHF106.46 and 200-day CHF99.17, momentum traders may watch pullbacks to the CHF106.5–CHF108.8 band as lower-risk entry points during this most-active session.
Meyka AI grades and NOVN.SW stock forecast
Meyka AI rates NOVN.SW with a score out of 100: 75.93 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and are not financial advice.
Meyka AI’s forecast model projects monthly CHF113.03, yearly CHF100.53, and five-year CHF123.85. Compared with the current CHF113.84, the one-year model implies -11.67% downside while the five-year forecast implies +8.80% upside. Forecasts are model-based projections and not guarantees.
Risks, sector view and NOVN.SW stock outlook
Key risks include pricing pressure in generics, Sandoz margin recovery timing, and regulatory outcomes for pipeline drugs. Novartis faces sector peers trading at higher PE multiples, but its return on equity 34.12% and ROIC 18.51% are competitive in Healthcare.
Sector performance shows Healthcare gains of 4.63% YTD; Novartis’s solid cash flow and dividend support a defensive tilt, yet investors should monitor liquidity and near-term earnings volatility ahead of the Feb 4 report.
Final Thoughts
NOVN.SW stock sits at CHF113.84 in the SIX pre-market session on 13 Jan 2026 amid heavy interest and below-average early volume. Fundamentals show robust cash flow per share CHF9.30 and EPS CHF5.83, supporting a fair-value PE-based reference near CHF116.60. Technicals flag short-term overbought conditions and an RSI of 74.23, so traders may prefer to wait for a pullback toward the CHF106.50–CHF108.80 range for better risk-reward. Meyka AI’s forecast model projects a one-year figure of CHF100.53 and a five-year target of CHF123.85, implying a short-term downside of -11.67% and a longer-term upside of +8.80% versus the current price. Meyka AI, our AI-powered market analysis platform, assigns a B+ (75.93) grade reflecting strong returns, solid cash flow, and sector positioning. Investors should weigh dividend income, pipeline catalysts, and the Feb 4 earnings date when sizing exposure. Forecasts are model projections and not guarantees.
FAQs
What is the current price and short-term trend for NOVN.SW stock?
NOVN.SW stock trades at CHF113.84 pre-market on 13 Jan 2026. The short-term trend shows overbought signals: RSI 74.23 and Stochastic %K 92.86, suggesting possible consolidation or a pullback in the coming sessions.
How does Novartis’s valuation compare to peers?
Novartis trades at PE 19.53, below some large healthcare peers by PE but above sector averages on price-to-book 6.34. Strong ROE 34.12% and free cash flow yield 6.68% help justify the premium multiples.
What are Meyka AI’s key forecasts for NOVN.SW stock?
Meyka AI’s forecast model projects one-year CHF100.53 (implied -11.67%) and five-year CHF123.85 (implied +8.80%) versus the current CHF113.84. These are model-based projections and not guarantees.
When is the next major catalyst for NOVN.SW stock?
Novartis will report earnings on 4 Feb 2026. That report is the primary near-term catalyst and could move the stock materially depending on Innovative Medicines results and Sandoz guidance.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
